Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519969 | 0.84 | GSK3B (0.50) | MEN1KMT2AROCK2ROCK1NPC1 | |
| SCHEMBL7522024 | 0.80 | KMT2A (0.62) | MEN1KMT2AEPHX2NPC1RAB9A | |
| SCHEMBL7516319 | 0.77 | RAB9A (0.52) | MEN1KMT2AROCK2ROCK1GAA | |
| SCHEMBL28566662 | 0.73 | RAB9A (0.66) | MEN1KMT2AROCK2MTORNPC1 | |
| SCHEMBL30050253 | 0.73 | RAB9A (0.66) | MEN1KMT2AROCK2MTORNPC1 | |
| SCHEMBL6190779 | 0.72 | TUBB4A (0.51) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL13647316 | 0.71 | GAA (0.54) | EPHX2GAAMTORNPC1RAB9A | |
| SCHEMBL7516899 | 0.71 | NPC1 (0.51) | MEN1KMT2AEPHX2NPC1RAB9A | |
| Lozilurea SCHEMBL1812194 | 0.70 | GAA (0.56) | MEN1KMT2AEPHX2GAAMTOR | |
| SCHEMBL7519777 | 0.69 | MEN1 (0.54) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | ROCHE DIAGNOSTICS GMBH | 2002-05-16 | — | — | US | disclosed |
| US-6333346-B1 | AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2001-12-25 | — | — | US | disclosed |
| EP-1009747-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012917-A1 | UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058694-A1 | Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents | UTS2R, SRD5A2, SRD5A1 | MEN1 3390/4885KMT2A 3288/4885ROCK2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.